Recombinant Anti-Fibulin-4 antibody [EPR684(2)] (ab125073)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR684(2)] to Fibulin-4
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Fibulin-4 antibody [EPR684(2)]
See all Fibulin-4 primary antibodies -
Description
Rabbit monoclonal [EPR684(2)] to Fibulin-4 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt,ICC/IF or IP -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide within Human Fibulin-4 aa 400-500. The exact sequence is proprietary.
-
Positive control
- JAR and SW480 cell lysates, Human fetal lung lysate, Human breast carcinoma and muscle tissues.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Constituents: 0.35% Sodium citrate, 0.17% Sodium chloride, 0.03% EDTA, 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR684(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab125073 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 49 kDa.
|
|
IHC-P | (2) |
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 49 kDa. |
IHC-P
1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Involvement in disease
Defects in EFEMP2 are a cause of cutis laxa autosomal recessive type 1 (ARCL1) [MIM:219100]. Hereditary cutis laxa refers to a heterogeneous group of connective tissue disorders characterized by cutaneous abnormalities and variable systemic manifestations. The most constant clinical feature is loose skin, sagging over the face and trunk. Hereditary cutis laxa is inherited in both autosomal dominant and autosomal recessive modes. ARCL1 shows the most severe phenotype and has the poorest prognosis. In addition to the skin, internal organs enriched in elastic fibers, such as the lung and arteries, are affected. -
Sequence similarities
Belongs to the fibulin family.
Contains 6 EGF-like domains. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 30008 Human
- Entrez Gene: 58859 Mouse
- Omim: 604633 Human
- SwissProt: O95967 Human
- SwissProt: Q9WVJ9 Mouse
- Unigene: 170622 Human
- Unigene: 276367 Mouse
-
Alternative names
- EFEMP 2 antibody
- EFEMP2 antibody
- EGF containing fibulin like extracellular matrix protein 2 antibody
see all
Images
-
All lanes : Anti-Fibulin-4 antibody [EPR684(2)] (ab125073) at 1/1000 dilution
Lane 1 : HEK-293T (human embryonic kidney) whole cell lysates
Lane 2 : HepG2 (human hepatocellular carcinoma) whole cell lysates
Lane 3 : Human fetal lung tissue lysates
Lane 4 : Human colon cancer tissue lysates
Lane 5 : Human placenta tissue lysates
Lane 6 : Mouse placenta tissue lysates
Lane 7 : Mouse lung tissue lysates
Lane 8 : NIH/3T3 (mouse embryo) whole cell lysates
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 49 kDa
Observed band size: 55 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking and diluting buffer: 5% NFDM/TBST
-
All lanes : Anti-Fibulin-4 antibody [EPR684(2)] (ab125073) at 1/1000 dilution
Lane 1 : JAR cell lysate
Lane 2 : SW480 cell lysate
Lane 3 : Human fetal lung tissue lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 49 kDa -
ab125073, at 1/250, staining Fibulin-4 in paraffin-embedded Human breast carcinoma tissue by immunohistochemistry.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
ab125073, at 1/250, staining Fibulin-4 in paraffin-embedded Human muscle tissue by immunohistochemistry.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab125073 has been referenced in 8 publications.
- Ortega MA et al. Contribution of the Elastic Component and Venous Wall Arterialization in Patients with Venous Reflux. J Pers Med 12:N/A (2022). PubMed: 35207748
- Song L et al. EFEMP2 Suppresses the Invasion of Lung Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition (EMT) and Down-Regulating MMPs. Onco Targets Ther 13:1375-1396 (2020). PubMed: 32110039
- Zhou Q et al. EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/ß-catenin signaling pathway in human bladder cancer. Int J Biol Sci 15:2139-2155 (2019). PubMed: 31592144
- Kang N et al. EFEMP2 Inhibits Breast Cancer Invasion And Metastasis In Vitro And In Vivo. Onco Targets Ther 12:8915-8933 (2019). PubMed: 31802903
- Wang T et al. Fibulin-4 is associated with prognosis of endometrial cancer patients and inhibits cancer cell invasion and metastasis via Wnt/ß-catenin signaling pathway. Oncotarget 8:18991-19012 (2017). ICC ; Human . PubMed: 28177909
- Zhang D et al. Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway. Int J Oncol 50:1513-1530 (2017). IHC-P, ICC/IF, WB ; Human . PubMed: 28339091
- Chen J et al. Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas. BMC Cancer 15:91 (2015). IHC . PubMed: 25885889
- Chen J et al. Overexpression of fibulin-4 is associated with tumor progression and poor prognosis in patients with cervical carcinoma. Oncol Rep 31:2601-10 (2014). PubMed: 24737201